BB BIOTECH AG
BB Biotech AG publishes its interim report
BB BIOTECH AG / Key word(s): Interim Report Media Release, April 24, 2020 BB Biotech AG publishes its interim report Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2020 amounted to CHF 758 mn (profit of CHF 890 mn in the same period 2019). For an investment company, the reported result reflects the performance of the stocks that it holds in its portfolio. BB Biotech AG’s interim report as at March 31, 2020 can be downloaded at www.bbbiotech.com For further information:
Company profile Disclaimer
24-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Phone: | +41 52 624 08 45 |
E-mail: | info@bbbiotech.com |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX |
EQS News ID: | 1028199 |
End of Announcement | DGAP News Service |